LHRH agonist Clinical Trials

2 actively recruiting trials across 1 location

▼ -1 trial since June 2026

Also known as: Goserelin, Leuprolide, Triptorelin

Pipeline

Phase 3: 2

Top Sponsors

Hoffmann-La Roche1
Fudan University1

Indications

Breast Cancer2
Cancer2
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer1

Other1 trial

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3

Daphne, Alabama1 trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Southern Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.